Kintor Pharmaceutical Limited is a clinical-stage biotechnology firm dedicated to the development and commercialization of a diverse pipeline of small molecule and biologic treatments. Its primary focus is on addressing androgen-receptor-related conditions where current medical options are lacking, serving patients both within the People's Republic of China and globally. The company's innovative pipeline features several key candidates, such as Proxalutamide, a next-generation androgen receptor (AR) antagonist currently being investigated for metastatic castration-resistant prostate cancer, AR-positive breast cancer, and COVID-19. Another notable compound is Pyrilutamide, also an AR antagonist, designed to treat androgenetic alopecia (AGA) and acne vulgaris. Kintor also has an ALK-1 antibody in its portfolio, aimed at metastatic hepatocellular carcinoma (HCC) and various other solid tumors. Additionally, GT20029, a topical AR-PROTAC compound, is under development for AGA and acne vulgaris. A dual-target antibody, PD-L1/TGF-ß, is being explored for its potential in treating non-small cell lung cancer, biliary tract cancer, triple-negative breast cancer, and HPV-associated tumors. Further contributing to its diverse offerings is Detorsertib, intended for metastatic solid tumors including breast, prostate, and HCC. Finally, a Hedgehog/SMO Inhibitor, which targets the hedgehog signal transduction pathway, is being developed for blood cancer and basal-cell carcinoma. Established in 2009, Kintor Pharmaceutical Limited maintains its headquarters in Suzhou, People's Republic of China.
—
Kintor Pharmaceutical Limited is a clinical-stage biotechnology firm dedicated to the development and commercialization of a diverse pipeline of small molecule and biologic treatments. Its primary focus is on addressing androgen-receptor-related conditions where current medical options are lacking, serving patients both within the People's Republic of China and globally. The company's innovative pipeline features several key candidates, such as Proxalutamide, a next-generation androgen receptor (AR) antagonist currently being investigated for metastatic castration-resistant prostate cancer, AR-positive breast cancer, and COVID-19. Another notable compound is Pyrilutamide, also an AR antagonist, designed to treat androgenetic alopecia (AGA) and acne vulgaris. Kintor also has an ALK-1 antibody in its portfolio, aimed at metastatic hepatocellular carcinoma (HCC) and various other solid tumors. Additionally, GT20029, a topical AR-PROTAC compound, is under development for AGA and acne vulgaris. A dual-target antibody, PD-L1/TGF-ß, is being explored for its potential in treating non-small cell lung cancer, biliary tract cancer, triple-negative breast cancer, and HPV-associated tumors. Further contributing to its diverse offerings is Detorsertib, intended for metastatic solid tumors including breast, prostate, and HCC. Finally, a Hedgehog/SMO Inhibitor, which targets the hedgehog signal transduction pathway, is being developed for blood cancer and basal-cell carcinoma. Established in 2009, Kintor Pharmaceutical Limited maintains its headquarters in Suzhou, People's Republic of China.
—
Daily adjusted close
Kintor Pharmaceutical Limited is a clinical-stage biotechnology firm dedicated to the development and commercialization of a diverse pipeline of small molecule and biologic treatments. Its primary focus is on addressing androgen-receptor-related conditions where current medical options are lacking, serving patients both within the People's Republic of China and globally. The company's innovative pipeline features several key candidates, such as Proxalutamide, a next-generation androgen receptor (AR) antagonist currently being investigated for metastatic castration-resistant prostate cancer, AR-positive breast cancer, and COVID-19. Another notable compound is Pyrilutamide, also an AR antagonist, designed to treat androgenetic alopecia (AGA) and acne vulgaris. Kintor also has an ALK-1 antibody in its portfolio, aimed at metastatic hepatocellular carcinoma (HCC) and various other solid tumors. Additionally, GT20029, a topical AR-PROTAC compound, is under development for AGA and acne vulgaris. A dual-target antibody, PD-L1/TGF-ß, is being explored for its potential in treating non-small cell lung cancer, biliary tract cancer, triple-negative breast cancer, and HPV-associated tumors. Further contributing to its diverse offerings is Detorsertib, intended for metastatic solid tumors including breast, prostate, and HCC. Finally, a Hedgehog/SMO Inhibitor, which targets the hedgehog signal transduction pathway, is being developed for blood cancer and basal-cell carcinoma. Established in 2009, Kintor Pharmaceutical Limited maintains its headquarters in Suzhou, People's Republic of China.